I'd hate to be short Pall (NYSE:PLL), as large companies in the filtration space often seem as close to bulletproof as you can find in the market. So even though sell-side analysts chronically overestimate Pall's free cash flow, investors remain happy with a company that admittedly enjoys strong share and a very lucrative channel of repeat business. While I think Pall's shares remain overvalued, I don't have any particular reason to believe that the shares will sell off dramatically, as the life sciences business should be stable and the industrial business should start improving next year.
On Target In Fiscal Q4
There are always plenty of moving parts within Pall's results, as the company sells into so many different end markets, but the end result performance was pretty much on target.
Revenue fell almost 1% as reported to close the fiscal year, but revenue in local currency terms rose half a point. Life sciences was up 6% for the quarter, as strength in biopharma offset weaker conditions in the Chinese and European food and beverage sector. Customer utilization levels in industrial markets remain a real issue, though, and the company saw a 5% decline (local currency) in industrial sales, with particular weakness in microelectronics and municipal water.
Improving the company's cost structure has been a key topic at Pall, though this quarter didn't really show the progress that the company has been making. Gross margin was flat, as a slight improvement in industrial was offset by a nearly one point decline in life sciences. Operating income declined 3% at the corporate level, while life sciences segment earnings were flat and industrial improved 1%.
Not Many Surprises, All Things Considered
This really looked like an “as expected” quarter all across the board. Pall's life science performance was consistent with an earlier report from Sartorius, while Donaldson (NYSE:DCI) reported weakness in the industrial sector and Entegris (Nasdaq:ENTG) gave weak guidance on the basis of soft trends in semiconductors and microelectronics.
There really isn't that much joy (or momentum) in industrial filtration/fluid handling right now. Leading fluid handling company IDEX (NYSE:IEX) saw just 2% organic sales growth in the calendar second quarter, though orders were better. Likewise, Xylem (NYSE:XYL), a “water technology” company, saw sales decline in the quarter, though Flowserve (NYSE:FLS) saw mid single-digit revneue growth. With industrial activity lower almost across the board, utilization rates have been quite poor (50% or below in some cases), and that has reduced the need for replacement consumables. As industrial activity picks up, so should Pall's industrial business, but management's guidance doesn't suggest a big recovery next year.
Strong Share And Ample Liquidity, Plus Cost-Cutting
I understand why Pall is popular. A very large percentage of the company's revenue comes from very profitable replacement/consumable components, and once the company makes a system sale, the relationship tends to be long and lucrative. Moreover, while Pall's products are quite profitable to them, they're typically not expensive enough to the end customers to justify replacing entire systems and interrupting operations.
It's also certainly true that the company's balance sheet is in good shape, which gives the company a lot of options in terms of returning capital to shareholders or growing the business through acquisitions. Last and not least, a relatively new management team still has room to maneuver with operational improvements that can boost margins.
The Bottom Line
The only thing I don't like about Pall is the price – this company rarely ever gets very cheap and investors are willing to pay a lot for its consistent cash flows. With that, even the fact that Wall Street sell-side analysis often over-estimate free cash flows doesn't really impact the stock. Not surprisingly, I don't think these shares are much of a bargain today, but I'd be in no rush to sell just on that basis.
Disclosure – At the time of writing, the author did not own shares of any company mentioned in this article.

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  9. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  10. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. Earnings Per Share - EPS

    The portion of a company's profit allocated to each outstanding ...
  5. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  6. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!